FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

November 30, 2015

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

Previous Article
Genome editing reagent launched for disease model generation
Genome editing reagent launched for disease model generation

AMSBIO has launched DNA-In® CRISPR – an innovative transfection reagent that simplifies and accelerates gen...

Next Article
Human Longevity announces acquisition of Cypher Genomics
Human Longevity announces acquisition of Cypher Genomics

Human Longevity, Inc., the genomics-based, technology-driven company, announced today that the company has ...